misleading statements

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.

Vistagen's failed drug trial caused 81% stock drop. Securities lawsuit filed for investors who bought shares April 2024-December 2025. Lead plaintiff deadline: March 16, 2026.

AGL faces securities fraud allegations over false 2025 guidance. Stock plunged 51.5% after guidance suspension; investors have until March 2026 deadline to join class action.

Law firm investigates Ramaco Resources for alleged securities fraud over inactive Wyoming mine despite reported groundbreaking. Class action deadline: March 31, 2026.

Pomdoctor investors must act by April 13, 2026, to join securities fraud class action alleging false statements and manipulated trading volumes that caused stock decline.

Rosen Law Firm sues Picard Medical for securities fraud involving false statements and market manipulation. Investors must act by April 13, 2026 deadline.

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.

Oracle faces securities fraud class action for allegedly misleading investors about AI infrastructure investments requiring substantial capital with minimal near-term revenue generation.

Class action lawsuit filed against Plug Power for allegedly making false statements about hydrogen facility development and DOE loan prospects. Investors who bought securities between January-November 2025 eligible.

Four companies face securities fraud lawsuits alleging false statements to investors. Shareholders have until March 2026 to become lead plaintiffs in the class actions.

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.

Schall Law Firm launches securities fraud class action against Vistagen for allegedly making misleading statements about fasedienol drug trial prospects, affecting investors from April 2024 to December 2025.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors claim the company concealed negative trial results.